Preclinical results show that KPT‐330 induces responses at well‐tolerated doses 35 and decreases Mcl‐1 protein levels.29 Higher XPO1 levels are associated with poor prognosis and targeting XPO1 by KPT‐330 has shown promise in clinical trials in targeting AML.26, 32 Our working hypothesis was that because XPO1 inhibition decreases Mcl‐1 protein levels, targeting XPO1 can synergize with ABT‐199 treatment in AML. Here, XPO1 is linked to acute myeloid leukemia.